

Table SI. Risk factors contributing to thrombotic burden related to patient, cancer, treatment and biomarkers. In the parentheses is displayed the number of cases and the relevant percentage.

Description	ProD tinzaparin dose (≤4,500 Anti-Xa IU; OD), n (%)	InterD tinzaparin dose (8.000-12.000 Anti-Xa IU; OD), n (%)	P-value	OR and 95% CI
Patient				
Age			0.0822	1.43 (0.95-2.15)
<65 years	85 (46.0)	76 (37.3)		
≥65 years	100 (54.1)	128 (62.7)		
Sex			0.0669	1.46 (0.97-2.18)
F	91 (49.5)	82 (40.2)		
M	93 (50.5)	122 (59.8)		
BMI (cut off 30)			0.0043	2.27 (1.28-4.01)
<30	165 (89.2)	160 (78.4)		
≥30	20 (10.8)	44 (21.6)		
BMI (cut off 35)			0.0251	3.06 (1.10-8.54)
<35	180 (97.3)	188 (92.2)		
≥35	5 (2.7)	16 (7.8)		
Ex or current smoker			0.0011	1.99 (1.31-3.01)
No	87 (47.0)	63 (30.9)		
Yes	98 (53.0)	141 (69.1)		
History of thrombosis			0.1254	4.64 (0.54-40.13)
No	183 (99.5)	197 (97.5)		
Yes	1 (0.5)	5 (2.5)		
History of surgery			<0.0001	0.43 (0.28-0.65)
No	84 (45.4)	134 (66.0)		
Yes	101 (54.6)	69 (34.0)		
History of trauma			0.0948 ^a	0.34 (0.09-1.28)
No	177 (95.7)	198 (98.5)		
Yes	8 (4.3)	3 (1.5)		
Cancer				
Metastatic disease			0.0007	2.13 (1.37-3.30)
No	72 (38.9)	47 (23.0)		
Yes	113 (61.1)	157 (77.0)		
Treatment				
HTBAs			0.3483	0.82 (0.53-1.25)
No	57 (30.8)	72 (35.3)		
Yes	128 (69.2)	132 (64.7)		
Radiotherapy			0.2752	1.28 (0.82-2.00)
No	133 (73.5)	134 (68.4)		
Yes	48 (26.5)	62 (31.6)		
Erythropoiesis agents			<0.0001	3.47 (1.93-6.25)
No	168 (90.8)	151 (74.0)		
Yes	17 (9.2)	53 (26.0)		
Biomarkers				
Pre chemotherapy leukocyte count >11x10 ⁹ /liter			0.1382	1.43 (0.89-2.29)
No	147 (79.5)	149 (73.0)		
Yes	38 (20.5)	55 (27.0)		
Pre chemotherapy PLT count ≥350x10 ⁹ /l			0.6809	1.09 (0.72-1.65)
No	118 (63.8)	126 (61.8)		
Yes	67 (36.2)	78 (38.2)		
Pre chemotherapy hemoglobin <100 g/liter			0.9995	1.00 (0.61-1.63)
No	146 (78.9)	161 (78.9)		
Yes	39 (21.1)	43 (21.1)		

^aFisher's exact test results, all other P-values from χ^2 tests. Univariate analysis of ProD vs. InterD of tinzaparin. 95% CI, 95% confidence interval; HTBAs, high thrombotic burden agents; InterD, intermediate dose; OR, odds ratio; PLT, platelet; ProD, prophylactic dose; Anti-Xa IU, Anti-Xa International Units; OD, once daily; OR, odds ratio.